CymaBay Therapeutics (CBAY) Misses Q2 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to CymaBay Therapeutics (CBAY) Misses Q2 EPS by 2c

CymaBay Reports Second Quarter and Six Months Ended June 30, 2022 Financial Results and Provides Corporate Update

August 11, 2022 4:05 PM EDT

Enrollment completed in RESPONSE with 193 patients enrolled in over 20 countries

Conference call and webcast today at 4:30 p.m. ET

NEWARK, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the second quarter ended June 30, 2022.

Sujal Shah, President and CEO of CymaBay, stated, We are elated to have finished enrollment in RESPONSE, our second, global Phase 3 study of seladelpar for... More